NCT00279773View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2007

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

TKI258

Trial Locations (1)

77020

The University of Texas, M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY